Mobile

A Phase 2 Study of Ruxolitinib With Capecitabine in Subjects With Advanced HER2-Negative Breast Cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-002620-26

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate and compare the OS of subjects with advanced or metastatic HER2 negative breast cancer when treated with ruxolitinib in combination with capecitabine versus capecitabine alone.

Critère d'inclusion

  • Metastatic or advanced HER-2 negative breast cancer patients who have already received treatment with anthracyclines and paclitaxel

Liens